Home epill Announces IPO Filing: Pioneering the Future of Electronic Pills in Digital Healthcare

epill Announces IPO Filing: Pioneering the Future of Electronic Pills in Digital Healthcare

Mar 03, 2022 09:37 CST Updated 09:37

While technological advancements have brought greater convenience and comfort to human life, they have also improved patients’ quality of life, serving as a boon to humanity. epill is one such example: when physicians are unable to treat patients in certain small and thin tissues, epill comes into its own. Under these circumstances, epill has begun to attract the attention of researchers.

What is epill?
epill, short for “Electronic Pill,” literally translated as “electronic pill,” is a diagnostic tool designed for situations in which physicians are unable to manually administer disease treatment.

The concept of the electronic pill (e-pill) emerged in 1972, when Professor John Cooper and Dr. Eric Johannessen from the University of Glasgow pioneered its development. Functioning similarly to a medical monitoring system, it can monitor parameters such as temperature, pH level, electrical conductivity, and dissolved oxygen, as well as capture images and transmit them to an external system. Early e-pills, which integrated sensor chips and connectors, measured approximately 55 mm in length and 16 mm in diameter, weighing 5 g. With technological advancements, current models have been reduced to 25 mm in length and 7 mm in diameter.

3


The electronic pill consists of four main components, including four microelectronic sensors, one ASIC chip, one wireless transmitter, and one power source.

2


Among them, the four microelectronic sensors are as follows: the first is a silicon diode for detecting body temperature; the second is an ion-sensitive field-effect transistor (ISFET) for measuring ion concentration; the third is a gold electrode to facilitate conductivity measurement; and the last is a three-electrode electrochemical sensor, which is used to calculate the rate of dissolved oxygen and identify the activity of aerobic bacteria in the small and large intestines. These sensors are controlled by a dedicated application-specific integrated circuit (ASIC). Meanwhile, all other components of the electronic pill are connected to the ASIC.

Moreover, the visualized electronic pill also requires a “camera” component to capture the entire image and transmit it wirelessly.

Once the entire component architecture is successfully integrated, the pill begins detecting diseases and abnormalities as it traverses the gastrointestinal tract. Due to its compact size, the electronic pill can easily reach areas such as the small and large intestines, transmitting information to external systems in real time, allowing all monitoring data to be displayed on a monitor. Upon entering the digestive system, it starts collecting data and sending it to a computer.

1


After diagnosis, the electronic pill is excreted intact along with metabolic waste. It also bears the resounding title of “the magic pill of the medical world,” as it facilitates easy monitoring of infection sites and abnormalities in infectious diseases.

As a novel medical device that generates power through contact with gastrointestinal fluids, such as acids and bases, the electronic pill can perform various therapeutic functions, including targeted drug delivery for certain types of cancer, stimulation of damaged tissue, measurement of biological indicators, or monitoring the status of chronic lesions such as gastric diseases. In addition, itAdditional advantages include:


  • Suitable for corrosive and static environments;


  • Can be used for water quality assessment, pollution detection, fermentation process control, and pipeline inspection in industrial applications;


  • Since electronic pills utilize a PROGRAMMABLE STANDBY MODE, their power consumption is extremely low;


  • Compact in size, highly suitable for practical application;


  • The cells have a very long lifespan and have low requirements for power, current, and voltage;


  • Reduce transmission distance, with no noise interference;



However, there are currently some limitations, such as:


  • Cannot perform ultrasound and electrical impedance tomography;


  • No abnormal radiation detected;


  • Radiotherapy associated with cancer and chronic inflammation cannot be administered;


  • The microelectronic pill is too expensive, making it inaccessible in many countries;


  • Difficult to digest for infants and young children;



Current Status and Application Prospects of e-Pill
In fact, Philips launched an electronic pill with intelligent drug-delivery capabilities as early as 2008. Subsequently, in 2012, the U.S. Food and Drug Administration (FDA) approved the integration of miniature ingestible chips into medications by Proteus, a UK-based smart medical device company. Last year, Google’s Advanced Technology and Projects (ATAP) division also partnered with Proteus to develop an emerging smart pill embedded with miniature wireless transmitters and sensors. Notably, another project under experimentation at Google—the modular smartphone Ara—aims to utilize smart pills as authentication terminals for future smart home devices. In the future, you will be able to control computers, home appliances, and other devices without any manual operation.

As policies are relaxed and technology advances, smart pills will be increasingly adopted by the global healthcare industry and other sectors.

未来


According to a research report released in early May by the U.S. market research firm Markets and Markets, the global ingestible sensor (electronic pill) market was valued at $1.56 billion in 2014. Over the following decade (2014–2024), this market is poised for rapid growth. During the forecast period from 2014 to 2020, it is projected to expand at a compound annual growth rate (CAGR) of 16.16%, reaching $3.83 billion by 2020. From 2020 to 2024, the market will continue its accelerated expansion, with a CAGR of 23.7%, and is expected to reach $8.98 billion by 2024.

General Advisor for VCBeat’s Glossary of Trending English Terms in Digital Health: Zhao Xinyuan, CEO of Beijing Intellifusion Technology Co., Ltd., and Member of the HL7 China Technical Steering Committee.

VCBeat is currently recruiting volunteers to analyze trending English terms in digital health. We welcome you to share your insights. Please follow the VCBeat WeChat official account and contact us!